A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder
Brief description of study
The goal of this phase II trial is to assess the efficacy of pembrolizumab added to concurrent radiation and gemcitabine as bladder-preserving treatment for patients with muscle-invasive urothelial cancer who are not candidates for or decline radical cystectomy.
Clinical Study Identifier: s15-00220
ClinicalTrials.gov Identifier: NCT02621151
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
